EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer

Morgann Hendrixson iD, Yevgeniy Gladkiy, Anita Thyagarajan, Ravi P Sahu iD

Medical Sciences · 07.04.2024 · 12 (2) · 20

DOI: 10.3390/medsci12020020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 07.04.2024. Verfasst von Morgann Hendrixson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Sorafenib, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIEHS R21.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungSorafenibLung NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsPhenylurea Compounds

Stichwörter der Autor:innen

cell signaling pathwaynon-small cell lung cancersorafenibtargeted therapy

Substanzen

SorafenibAntineoplastic AgentsProtein Kinase InhibitorsPhenylurea Compounds

Autor:innen und Institutionen

  • Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
  • Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.

ORCID-Profile: Morgann Hendrixson, Ravi P Sahu

Förderung

  • NIEHS NIH HHS
  • NIEHS R21

Zitieren

APA

Hendrixson, M., Gladkiy, Y., Thyagarajan, A., & Sahu, R. P. (2024). Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer. Medical Sciences, 12(2), 20. https://doi.org/10.3390/medsci12020020

Vancouver

Hendrixson M, Gladkiy Y, Thyagarajan A, Sahu RP. Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer. Medical Sciences. 2024;12(2):20. doi:10.3390/medsci12020020

BibTeX
@article{Hendrixson2024,
  author = {Hendrixson, Morgann and Gladkiy, Yevgeniy and Thyagarajan, Anita and Sahu, Ravi P},
  title = {Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer},
  journal = {Medical Sciences},
  year = {2024},
  volume = {12},
  number = {2},
  pages = {20},
  doi = {10.3390/medsci12020020}
}
Kostenlos starten →